UNSPSC 85753414: Revision of autologous tissue substitute in scrotum and tunica vaginalis, percutaneous endoscopic approach

This classification denotes the group of activities that yields a surgical intervention or procedure to revision of autologous tissue substitute in scrotum and tunica vaginalis, percutaneous endoscopic approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0VW847Z

UNSPSC 85753414, Revision of autologous tissue substitute in scrotum and tunica vaginalis, percutaneous endoscopic approach, is a Commodity code that shows little relevant recent activity. The code's nominal scope describes a specific urological surgical procedure, but state and local procurement activity recorded under this code does not correspond to that clinical intervention. Recent opportunities tagged to this code span independent medical evaluation services for public safety pension disability determinations, surgical benefits carve-out programs for municipal employee health plans, occupational medical surveillance for ferry workers, emergency and specialty healthcare services for detained youth, pharmacy benefit management administration, and temporary clinical staffing placement — none of which involve autologous tissue revision or the procedure specified in the code name.

The mismatch between the code's procedural description and the actual work being solicited suggests either miscoding in source records or use of this Commodity code as a catch-all for medical services procurement. The issuing bodies span county governments (Harris County, Collier County, Santa Clara County), city municipalities (Phoenix, Long Beach), and state transportation agencies (Washington State Department of Transportation). Geographic activity appears across Arizona, California, Florida, and Washington, with no dominant jurisdiction. Without evidence of state and local procurement aligned to the code's stated clinical scope, the code does not currently represent a coherent market opportunity.